Stay updated with breaking news from Nasdaq Spry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leerink Partnrs cut shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from an outperform rating to a market perform rating in a research report released on Thursday morning, PriceTargets.com reports. A number of other research analysts have also recently issued reports on the stock. SVB Leerink cut shares of ARS Pharmaceuticals from an outperform rating […]
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was downgraded by equities researchers at Leerink Partnrs from an “outperform” rating to a “market perform” rating in a research note issued on Thursday, PriceTargets.com reports. Other equities analysts also recently issued research reports about the company. William Blair cut ARS Pharmaceuticals from an “outperform” rating to a […]
Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under...
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Ra Capital Management, L.P. bought 3,750,000 shares of the stock in a transaction that occurred on Tuesday, August 29th. The stock was acquired at an average price of $6.20 per share, for a total transaction of $23,250,000.00. Following the acquisition, the director now directly owns 5,856,774 […]
Wedbush restated their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a research report released on Monday morning, Benzinga reports. They currently have a $15.00 target price on the stock. Wedbush also issued estimates for ARS Pharmaceuticals’ Q4 2023 earnings at ($0.16) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at […]